Search Results - "KORKOLA, James E"

Cellular senescence in cancer: from mechanisms to detection by Ou, Hui‐Ling, Hoffmann, Reuben, González‐López, Cristina, Doherty, Gary J., Korkola, James E., Muñoz‐Espín, Daniel

“…Cellular senescence is considered a crucial process for tumour suppression, which can be facilitated by immune surveillance. However, when senescent cells…”
Get full text

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion by Jiao, Xuanmao, Velasco-Velázquez, Marco A, Wang, Min, Li, Zhiping, Rui, Hallgeir, Peck, Amy R, Korkola, James E, Chen, Xuelian, Xu, Shaohua, DuHadaway, James B, Guerrero-Rodriguez, Sandra, Addya, Sankar, Sicoli, Daniela, Mu, Zhaomei, Zhang, Gang, Stucky, Andres, Zhang, Xi, Cristofanilli, Massimo, Fatatis, Alessandro, Gray, Joe W, Zhong, Jiang F, Prendergast, George C, Pestell, Richard G

“…The functional significance of the chemokine receptor CCR5 in human breast cancer epithelial cells is poorly understood. Here, we report that CCR5 expression…”
Get full text

Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease by Butler, Timothy M, Johnson-Camacho, Katherine, Peto, Myron, Wang, Nicholas J, Macey, Tara A, Korkola, James E, Koppie, Theresa M, Corless, Christopher L, Gray, Joe W, Spellman, Paul T

“…The identification of the molecular drivers of cancer by sequencing is the backbone of precision medicine and the basis of personalized therapy; however,…”
Get full text

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease by Smith, Rebecca, Liu, Moqing, Liby, Tiera, Bayani, Nora, Bucher, Elmar, Chiotti, Kami, Derrick, Daniel, Chauchereau, Anne, Heiser, Laura, Alumkal, Joshi, Feiler, Heidi, Carroll, Peter, Korkola, James E.

“…Representative in vitro model systems that accurately model response to therapy and allow the identification of new targets are important for improving our…”
Get full text

INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer by Liu, Moqing, Smith, Rebecca, Liby, Tiera, Chiotti, Kami, López, Claudia S, Korkola, James E

“…Resistance to HER2-targeted therapeutics remains a significant clinical problem in HER2+ breast cancer patients with advanced disease. This may be particularly…”
Get full text

Subtype and pathway specific responses to anticancer compounds in breast cancer by Heiser, Laura M, Sadanandam, Anguraj, Kuo, Wen-Lin, Benz, Stephen C, Goldstein, Theodore C, Ng, Sam, Gibb, William J, Wang, Nicholas J, Ziyad, Safiyyah, Tong, Frances, Bayani, Nora, Hu, Zhi, Billig, Jessica I, Dueregger, Andrea, Lewis, Sophia, Jakkula, Lakshmi, Korkola, James E, Durinck, Steffen, Pepin, François, Guan, Yinghui, Purdom, Elizabeth, Neuvial, Pierre, Bengtsson, Henrik, Wood, Kenneth W, Smith, Peter G, Vassilev, Lyubomir T, Hennessy, Bryan T, Greshock, Joel, Bachman, Kurtis E, Hardwicke, Mary Ann, Park, John W, Marton, Laurence J, Wolf, Denise M, Collisson, Eric A, Neve, Richard M, Mills, Gordon B, Speed, Terence P, Feiler, Heidi S, Wooster, Richard F, Haussler, David, Stuart, Joshua M, Gray, Joe W, Spellman, Paul T

“…Breast cancers are comprised of molecularly distinct subtypes that may respond differently to pathway-targeted therapies now under development. Collections of…”
Get full text

A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma by Collisson, Eric A, Trejo, Christy L, Silva, Jillian M, Gu, Shenda, Korkola, James E, Heiser, Laura M, Charles, Roch-Philippe, Rabinovich, Brian A, Hann, Byron, Dankort, David, Spellman, Paul T, Phillips, Wayne A, Gray, Joe W, McMahon, Martin

“…KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA) but remains an intractable pharmacologic target. Consequently, defining RAS effector…”
Get more information

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer by Coleman, Daniel J., Gao, Lina, Schwartzman, Jacob, Korkola, James E., Sampson, David, Derrick, Daniel S., Urrutia, Joshua, Balter, Ariel, Burchard, Julja, King, Carly J., Chiotti, Kami E., Heiser, Laura M., Alumkal, Joshi J.

“…The BET bromodomain protein BRD4 is a chromatin reader that regulates transcription, including in cancer. In prostate cancer, specifically, the anti-tumor…”
Get full text

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA by Garay, Joseph P, Smith, Rebecca, Devlin, Kaylyn, Hollern, Daniel P, Liby, Tiera, Liu, Moqing, Boddapati, Shanta, Watson, Spencer S, Esch, Amanda, Zheng, Ting, Thompson, Wallace, Babcock, Darcie, Kwon, Sunjong, Chin, Koei, Heiser, Laura, Gray, Joe W, Korkola, James E

“…HER2-amplified breast cancer is a clinically defined subtype of breast cancer for which there are multiple viable targeted therapies. Resistance to these…”
Get full text

Annot: a Django-based sample, reagent, and experiment metadata tracking system by Bucher, Elmar, Claunch, Cheryl J, Hee, Derrick, Smith, Rebecca L, Devlin, Kaylyn, Thompson, Wallace, Korkola, James E, Heiser, Laura M

“…In biological experiments, comprehensive experimental metadata tracking - which comprises experiment, reagent, and protocol annotation with controlled…”
Get full text

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes by Yu, Katharine, Basu, Amrita, Yau, Christina, Wolf, Denise M, Goodarzi, Hani, Bandyopadhyay, Sourav, Korkola, James E, Hirst, Gillian L, Asare, Smita, DeMichele, Angela, Hylton, Nola, Yee, Douglas, Esserman, Laura, van 't Veer, Laura, Sirota, Marina

“…Drug resistance is a major obstacle in cancer treatment and can involve a variety of different factors. Identifying effective therapies for drug resistant…”
Get full text

Bladder Cancer Outcome and Subtype Classification by Gene Expression by BLAVERI, Ekaterini, SIMKO, Jeff P, WALDMAN, Frederic M, KORKOLA, James E, BREWER, Jeremy L, BAEHNER, Frederick, MEHTA, Kshama, DEVRIES, Sandy, KOPPIE, Theresa, PEJAVAR, Sunanda, CARROLL, Peter

“…Models of bladder tumor progression have suggested that genetic alterations may determine both phenotype and clinical course. We have applied expression…”
Get full text

Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors by KORKOLA, James E, HOULDSWORTH, Jane, FELDMAN, Darren R, OLSHEN, Adam B, QIN, Li-Xuan, PATIL, Sujata, REUTER, Victor E, BOSL, George J, CHAGANTI, R. S. K

“…Germ cell tumor (GCT) is the most common malignancy in young adult men. Currently, patients are risk-stratified on the basis of clinical presentation and serum…”
Get full text

Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach by Korkola, James E, Heck, Sandy, Olshen, Adam B, Feldman, Darren R, Reuter, Victor E, Houldsworth, Jane, Bosl, George J, Chaganti, R S K

“…Germ Cell Tumors (GCT) have a high cure rate, but we currently lack the ability to accurately identify the small subset of patients who will die from their…”
Get full text

The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression by Littlepage, Laurie E, Adler, Adam S, Kouros-Mehr, Hosein, Huang, Guiqing, Chou, Jonathan, Krig, Sheryl R, Griffith, Obi L, Korkola, James E, Qu, Kun, Lawson, Devon A, Xue, Qing, Sternlicht, Mark D, Dijkgraaf, Gerrit J P, Yaswen, Paul, Rugo, Hope S, Sweeney, Colleen A, Collins, Colin C, Gray, Joe W, Chang, Howard Y, Werb, Zena

“…The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20% to 30% of primary human breast cancers and that…”
Get more information

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer by Korkola, James E, Collisson, Eric A, Heiser, Laura, Oates, Chris, Bayani, Nora, Itani, Sleiman, Esch, Amanda, Thompson, Wallace, Griffith, Obi L, Wang, Nicholas J, Kuo, Wen-Lin, Cooper, Brian, Billig, Jessica, Ziyad, Safiyyah, Hung, Jenny L, Jakkula, Lakshmi, Feiler, Heidi, Lu, Yiling, Mills, Gordon B, Spellman, Paul T, Tomlin, Claire, Mukherjee, Sach, Gray, Joe W

“…We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2(+) breast cancers. We…”
Get full text

Biology and Genetics of Adult Male Germ Cell Tumors by HOULDSWORTH, Jane, KORKOLA, James E, BOSL, George J, CHAGANTI, R. S. K

“…Adult male germ cell tumors (GCTs) arise by transformation of totipotent germ cells. They have the unique potential to activate molecular pathways, in part…”
Get full text

A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses by Gross, Sean M., Dane, Mark A., Smith, Rebecca L., Devlin, Kaylyn L., McLean, Ian C., Derrick, Daniel S., Mills, Caitlin E., Subramanian, Kartik, London, Alexandra B., Torre, Denis, Evangelista, John Erol, Clarke, Daniel J. B., Xie, Zhuorui, Erdem, Cemal, Lyons, Nicholas, Natoli, Ted, Pessa, Sarah, Lu, Xiaodong, Mullahoo, James, Li, Jonathan, Adam, Miriam, Wassie, Brook, Liu, Moqing, Kilburn, David F., Liby, Tiera A., Bucher, Elmar, Sanchez-Aguila, Crystal, Daily, Kenneth, Omberg, Larsson, Wang, Yunguan, Jacobson, Connor, Yapp, Clarence, Chung, Mirra, Vidovic, Dusica, Lu, Yiling, Schurer, Stephan, Lee, Albert, Pillai, Ajay, Subramanian, Aravind, Papanastasiou, Malvina, Fraenkel, Ernest, Feiler, Heidi S., Mills, Gordon B., Jaffe, Jake D., Ma’ayan, Avi, Birtwistle, Marc R., Sorger, Peter K., Korkola, James E., Gray, Joe W., Heiser, Laura M.

“…The phenotype of a cell and its underlying molecular state is strongly influenced by extracellular signals, including growth factors, hormones, and…”
Get full text

Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer by Korkola, James E, Collisson, Eric A, Heiser, Laura M, Oates, Chris, Bayani, Nora, Itani, Sleiman, Esch, Amanda, Thompson, Wallace, Griffith, Obi L, Wang, Nicholas J, Kuo, Wen-Lin, Cooper, Brian, Billig, Jessica, Ziyad, Safiyyah, Hung, Jenny L, Jakkula, Lakshmi, Feiler, Heidi, Lu, Yiling, Mills, Gordon B, Spellman, Paul T, Tomlin, Claire, Mukherjee, Sach, Gray, Joe W

“…[This corrects the article DOI: 10.1371/journal.pone.0133219.]…”
Get full text

Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma by Shelley Hwang, E., Nyante, Sarah J., Yi Chen, Yunn, Moore, Dan, DeVries, Sandy, Korkola, James E., Esserman, Laura J., Waldman, Frederic M.

“…BACKGROUND Lobular carcinoma in situ (LCIS) of the breast is considered a marker for an increased risk of carcinoma in both breasts. However, the frequent…”
Get full text